Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Haven, an sun protectant product that reduces plant stress and dehydration; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Further, it provides Stargus and Amplitude, a biofungicide for improving plant health. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
SymbolNASDAQ:MBII
CUSIPN/A
Phone530-750-2800
Debt
Debt-to-Equity Ratio1.40
Current Ratio2.63
Quick Ratio1.76
Price-To-Earnings
Trailing P/E Ratio-1.73
Forward P/E Ratio-10.53
P/E GrowthN/A
Sales & Book Value
Annual Sales$18.17 million
Price / Sales10.89
Cash FlowN/A
Price / CashN/A
Book Value($1.62) per share
Price / Book-1.10
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-30,920,000.00
Net Margins-144.82%
Return on EquityN/A
Return on Assets-62.44%
Miscellaneous
Employees103
Outstanding Shares110,590,000
Market Cap$196.02 million
Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions
What is Marrone Bio Innovations' stock symbol?
Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."
How were Marrone Bio Innovations' earnings last quarter?
Marrone Bio Innovations Inc (NASDAQ:MBII) released its quarterly earnings results on Tuesday, August, 14th. The basic materials company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. The basic materials company earned $5.75 million during the quarter, compared to analyst estimates of $7.01 million. View Marrone Bio Innovations' Earnings History.
When is Marrone Bio Innovations' next earnings date?
What price target have analysts set for MBII?
2 brokerages have issued 12 month price objectives for Marrone Bio Innovations' shares. Their forecasts range from $1.55 to $4.00. On average, they anticipate Marrone Bio Innovations' share price to reach $2.7750 in the next year. This suggests a possible upside of 55.0% from the stock's current price. View Analyst Price Targets for Marrone Bio Innovations.
What is the consensus analysts' recommendation for Marrone Bio Innovations?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marrone Bio Innovations.
What are Wall Street analysts saying about Marrone Bio Innovations stock?
Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
- 1. HC Wainwright analysts commented, "We believe the company has room to continue improving margins as sales scale but expect some variability on a quarterly basis driven by sales mix. The company generated a net loss of $4.8M or $0.04 per share in 2Q18 compared to a net loss of $7.4M or $0.25 per share in 2Q17. the company had cash of $24.9M (including approximately $1.6M in short- and long-term restricted cash), and debt of $21.8M. Key takeaways. The company’s top line performance remained relatively flat compared to last year despite a broader portfolio of offerings in the market and wider geographic coverage." (8/15/2018)
- 2. According to Zacks Investment Research, "Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. " (7/18/2018)
Who are some of Marrone Bio Innovations' key competitors?
Some companies that are related to Marrone Bio Innovations include American Vanguard (AVD), Calyxt (CLXT), CVR Partners (UAN), Wynnstay Group (WYN), Evogene (EVGN), China Green Agriculture (CGA), Eden Research (EDEN), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Bion Environmental Technologies (BNET), Arcadia Biosciences (RKDA), Cavitation Technologies (CVAT) and Syngenta (SYT).
Who are Marrone Bio Innovations' key executives?
Marrone Bio Innovations' management team includes the folowing people:
- Dr. Pamela G. Marrone, Founder, CEO & Director (Age 61)
- Mr. James B. Boyd, Pres & CFO (Age 65)
- Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 71)
- Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 63)
- Mr. Brian R. Ahrens, VP of Sales & Bus. Devel. (Age 47)
Has Marrone Bio Innovations been receiving favorable news coverage?
Media stories about MBII stock have trended positive on Friday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a coverage optimism score of 0.43 on Accern's scale. They also gave press coverage about the basic materials company an impact score of 48.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Marrone Bio Innovations.
Who are Marrone Bio Innovations' major shareholders?
Marrone Bio Innovations' stock is owned by many different of institutional and retail investors. Top institutional investors include Waddell & Reed Financial Inc. (4.62%), BlackRock Inc. (2.64%), ICM Asset Management Inc. WA (0.24%), Bank of New York Mellon Corp (0.11%), Schwab Charles Investment Management Inc. (0.10%) and Spark Investment Management LLC (0.09%). Company insiders that own Marrone Bio Innovations stock include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Institutional Ownership Trends for Marrone Bio Innovations.
Which major investors are selling Marrone Bio Innovations stock?
MBII stock was sold by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc.. Company insiders that have sold Marrone Bio Innovations company stock in the last year include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Insider Buying and Selling for Marrone Bio Innovations.
Which major investors are buying Marrone Bio Innovations stock?
MBII stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., ICM Asset Management Inc. WA, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Spark Investment Management LLC. Company insiders that have bought Marrone Bio Innovations stock in the last two years include Ardsley Advisory Partners and Waddell & Reed Financial Inc. View Insider Buying and Selling for Marrone Bio Innovations.
How do I buy shares of Marrone Bio Innovations?
Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marrone Bio Innovations' stock price today?
One share of MBII stock can currently be purchased for approximately $1.79.
How big of a company is Marrone Bio Innovations?
Marrone Bio Innovations has a market capitalization of $196.02 million and generates $18.17 million in revenue each year. The basic materials company earns $-30,920,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Marrone Bio Innovations employs 103 workers across the globe.
How can I contact Marrone Bio Innovations?
Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]
MarketBeat Community Rating for Marrone Bio Innovations (NASDAQ MBII)
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
